Interview with OKYO Pharma CEO to air on Bloomberg TV

LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies to treat inflammatory dry eye disease (DED), a multi-billion dollar market, and anterior segment diseases including neuropathic…